KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Net Cash Flow for 8 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 58.49% to $15.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.4 million through Dec 2025, up 230.2% year-over-year, with the annual reading at $22.4 million for FY2025, 230.2% up from the prior year.
  • Net Cash Flow hit $15.5 million in Q4 2025 for Adaptive Biotechnologies, up from $11.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $141.1 million in Q3 2022 to a low of -$127.6 million in Q4 2022.
  • Historically, Net Cash Flow has averaged -$2.6 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 328.42% in 2022; the steepest drop was 865.46% in 2022.
  • Year by year, Net Cash Flow stood at $16.7 million in 2021, then plummeted by 865.46% to -$127.6 million in 2022, then surged by 81.47% to -$23.6 million in 2023, then skyrocketed by 141.27% to $9.8 million in 2024, then soared by 58.49% to $15.5 million in 2025.
  • Business Quant data shows Net Cash Flow for ADPT at $15.5 million in Q4 2025, $11.8 million in Q3 2025, and -$7.5 million in Q2 2025.